Commencement of share buyback programme

Fever-Tree today announces the commencement of a share buyback programme regarding the purchase of ordinary shares in the Company with a nominal value of 0.25 pence each (the "Shares") up to a maximum consideration of £71 million (the "Programme").

Fever-Tree previously announced its intention to commence the Programme on 30 January 2025, alongside the announcement its strategic partnership with Molson Coors for the exclusive sales, distribution and production of the Fever-Tree brand in the US.

Fever-Tree has entered into a non-discretionary agreement with Investec Bank plc ("Investec") to purchase Shares on its behalf and to make trading decisions independently of the Company. The Programme will commence today, 17 February 2025, and end no later than 30 September 2025. The sole purpose of the Programme is to reduce the share capital of Fever-Tree. As such, the Company intends to cancel any Shares purchased.

Any purchase of Shares under the Programme will be executed in accordance with certain pre-set parameters and in accordance with the Company's existing general authority to repurchase Shares granted by its shareholders at the annual general meeting held on 6 June 2024 (which permits the Company to purchase no more than 11,668,664 Shares), the Market Abuse Regulation (596/2014) as it forms part of domestic law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (as amended) and UKLR 9.6.2 using the average daily volume of Ordinary Shares traded in January 2025, being the month preceding the month of this announcement. The Company may repurchase up to 25% of this average daily volume per day during the programme.